Surface Oncology, Inc. (SURF)

NASDAQ: SURF · IEX Real-Time Price · USD
1.67
+0.03 (1.83%)
At close: Jul 1, 2022 4:00 PM
1.72
+0.05 (2.99%)
After-hours: Jul 1, 2022 4:35 PM EDT
1.83%
Market Cap 91.20M
Revenue (ttm) 31.06M
Net Income (ttm) -56.73M
Shares Out 54.61M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 346,916
Open 1.63
Previous Close 1.64
Day's Range 1.61 - 1.73
52-Week Range 1.37 - 8.38
Beta 1.68
Analysts Buy
Price Target 11.63 (+596.4%)
Earnings Date Aug 4, 2022

About SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibit... [Read more...]

Industry Biotechnology
IPO Date Apr 19, 2018
CEO J. Jeffrey Goater
Employees 67
Stock Exchange NASDAQ
Ticker Symbol SURF
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for SURF stock is "Buy." The 12-month stock price forecast is 11.63, which is an increase of 596.41% from the latest price.

Price Target
$11.63
(596.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Surface Oncology Appoints Carsten Brunn to Board of Directors

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Car...

- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer -

Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor micro...

Surface Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022

– Cash runway extended into 2024 –

Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma ...

Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche

Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022

Poster presentation highlights translational work supporting recommended dosing for SRF388 Phase 2 trials Poster presentation highlights translational work supporting recommended dosing for SRF388 Phase...

Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor micr...

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

Surface Oncology Appoints Theresa Boni as General Counsel

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir...

Trading Penny Stocks? Top Stock Market News for March 11th, 2022

What you need to know about trading penny stocks on March 11th The post Trading Penny Stocks? Top Stock Market News for March 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Other symbols: PZGVEON

Why Surface Oncology (SURF) Might Surprise This Earnings Season

Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021

Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types

Surface Oncology, Inc. (SURF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen's 42nd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings

Cathie Wood stocks to watch right now. The post 7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Surface Oncology Appoints Denice Torres as Chair of the Board of Directors

Biopharma veteran Ben Hickey appointed to Board of Directors

Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncol...

Gastric cancer trial in combination with pembrolizumab currently enrolling; first-line combination cohort for pancreatic cancer planned Gastric cancer trial in combination with pembrolizumab currently e...

Surface Oncology Named a 2021 Top Place to Work by the Boston Globe

Award recognizes the best employers in Massachusetts Award recognizes the best employers in Massachusetts

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical O...

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenviro...

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG

Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study